Clinical Trials
33 trialsNCT05243550 2026-05-11
ENVISION
UroGen Pharma Ltd.
Phase 3 Active not recruiting
NCT03757949 2026-05-04
Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT03732677 2026-03-13
NIAGARA
AstraZeneca
Phase 3 Active not recruiting
NCT04165317 2026-01-22
CREST
Pfizer
Phase 3 Active not recruiting
NCT03474107 2026-01-09
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Astellas Pharma Inc
Phase 3 Completed
NCT04149574 2025-09-16
CheckMate 7G8
Bristol-Myers Squibb
Phase 3 Terminated
NCT02807636 2025-02-24
IMvigor130
Hoffmann-La Roche
Phase 3 Completed
NCT05600322 2024-10-03
Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer
Photocure
Phase 3 Completed
NCT05136898 2024-09-19
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 3 Completed
NCT04209114 2024-06-27
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT04688931 2024-06-06
ATLAS
UroGen Pharma Ltd.
Phase 3 Terminated
NCT02603432 2024-03-27
JAVELIN Bladder 100
Pfizer
Phase 3 Completed
NCT02426125 2023-08-21
RANGE
Eli Lilly and Company
Phase 3 Completed
NCT02449239 2023-07-24
VISTA
Sesen Bio, Inc.
Phase 3 Completed
NCT02695771 2023-04-21
BIC
Corewell Health West
Phase 3 Completed
NCT02563561 2021-10-27
A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT03224182 2021-09-28
A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT02256436 2021-09-20
MK-3475-045
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00461591 2021-03-30
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT00445601 2020-01-18
S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
SWOG Cancer Research Network
Phase 3 Completed
NCT02302807 2019-08-01
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
Hoffmann-La Roche
Phase 3 Completed
NCT02560584 2018-07-02
A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting
Photocure
Phase 3 Completed
NCT01469221 2017-12-15
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT00598806 2017-11-13
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT01310803 2017-10-05
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
Phase 3 Terminated
NCT01200992 2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3 Terminated
NCT00005047 2017-06-08
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
SWOG Cancer Research Network
Phase 3 Terminated
NCT01410565 2016-12-13
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT00974818 2015-11-20
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase 3 Terminated
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00233402 2013-10-11
Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy
Photocure
Phase 3 Completed
NCT00412971 2013-10-11
A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer
Photocure
Phase 3 Completed
NCT00191477 2009-10-28
Instillation of Gemcitabine in Patients With Superficial Bladder Cancer
Eli Lilly and Company
Phase 3 Terminated